We had a great day yesterday at IPBC Australasia – an event that brings together IP firms, leading corporates, research institutions and governmental agencies to discuss core themes of IP value creation and strategic corporate IP best practice. POF’s Managing Partner, Ross McFarlane, moderated the session ‘IP in the Round’ and discussed the full circle …
>> Read more
Friday 19 October is Loud Shirt Day! As part of the POF Group’s approach to diversity and inclusion, we have gotten loud for deaf kids! Loud Shirt Day is a great way to educate the community and understand hearing issues, spreading the message that deaf children can learn to listen and speak through early intervention. …
>> Read more
It’s risky business bringing proceedings for IP infringement without proper legal advice. A self-represented Debra Crocker learnt this the hard way over a series of court proceedings, which saw her sentenced to time in prison for contempt of Court and prohibited from instituting proceedings in the Federal Court with limited exception. Following these recent proceedings,[1] …
>> Read more
Australian Federal Court not impressed with parallel AU/US proceedings Earlier this year, in a decision¹ made by O’Callaghan J of the Federal Court of Australia, Kraft was restrained from proceeding with arbitration proceedings against Bega in the US. The dispute arose in the context of the sale and promotion of BEGA branded peanut butter produced …
>> Read more
In what is a quite recent but unpublicised development, IP Australia now record “special” non-English characters (i.e. accented letters, umlauts, diaeresis and the like) for applicants and inventor names on new incoming patent applications. Until recently, an inventor named, for example, Åsa or Björn in a PCT national phase entry designating Australia would be recorded …
>> Read more
The first interlocutory injunction restraining the launch of a biosimilar pharmaceutical product was granted by the Federal Court of Australia in a decision on 12 June 2018¹. Background The decision concerns the monoclonal antibody rituximab, a biologic therapy which is prescribed in Australia to treat a number of immunology conditions including lymphoma, chronic lymphocytic leukaemia …
>> Read more
A recent opposition decision of the Australian Patent Office¹ focused on the level of disclosure which is required in a patent specification to properly enable and support the claimed invention. This decision illustrates the importance of providing an enabling disclosure across the full width of the claimed invention and, where possible, providing a principle of …
>> Read more
We hosted a morning tea in recognition of RSPCA Cupcake Day to raise much needed funds for the RSPCA. Cupcake Day is the sweetest opportunity of the year to raise money for animals in need, and all funds raised goes directly towards helping the abandoned, neglected and surrendered animals around the country that turn to the …
>> Read more
The power of the Registrar to correct errors appearing in the Trade Marks Register appears to have been curtailed by the recent decision of the Full Court in Vokes v Laminar Air Flow[1]. Vokes was the original owner of a series of trade marks however, an incorrectly filed change of name form (in circumstances where …
>> Read more
